Cerebral Palsy and Epilepsy in Children: Clinical Perspectives on a Common Comorbidity

Piero Pavone1, Carmela Gulizia2, Alice Le Pira1

  • 1Unit of Clinical Pediatrics, Department of Clinical and Experimental Medicine, AOU "Policlinico", PO "G. Rodolico", University of Catania, 95123 Catania, Italy.

Insights

Epilepsy is a common comorbidity in children with cerebral palsy (CP), particularly those with severe motor impairments. Early identification and treatment of epilepsy in CP patients are crucial for better outcomes.

Area of Science:

  • Pediatric Neurology
  • Childhood Disability Studies
  • Epileptology

Background:

  • Cerebral palsy (CP) is a leading cause of childhood disability.
  • Epilepsy affects approximately 40% of children with CP, representing a significant comorbidity.
  • Understanding the relationship between CP types and epilepsy is crucial for patient management.

Purpose of the Study:

  • To analyze clinical aspects of different cerebral palsy (CP) types.
  • To investigate the relationship between clinical data and CP types in children with comorbid epilepsy.
  • To report on the experience of analyzing CP and epilepsy comorbidities.

Main Methods:

  • Retrospective, single-center study involving 93 children with CP.
  • Classification of CP based on motor presentation (spastic quadriplegia, hemiplegia, diplegia, etc.).
  • Comparison of children with CP and epilepsy (n=46) against a control group of children with epilepsy without other neurological disorders (n=136).

Main Results:

  • Spastic hemiplegia was the most common CP type (42%) among the studied CP cohort.
  • Epilepsy frequency was higher in CP children with severe motor dysfunction (GMFCS IV-V).
  • Children with CP and epilepsy had a significantly earlier age of epilepsy onset (21 months) compared to controls (67 months).

Conclusions:

  • Epilepsy is a highly prevalent comorbidity in cerebral palsy.
  • Children with CP, especially those with major motor dysfunction, require careful monitoring for epilepsy.
  • Early detection and management of epilepsy in children with CP are essential.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
900
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.0K
Language and Cognition01:27

Language and Cognition

Language serves as a bridge between ideas and communication, influencing how individuals perceive and interact with the world. Psychologists have long debated whether language shapes thought or vice versa. This discussion gained grip with Edward Sapir and Benjamin Lee Whorf in the 1940s, who proposed that language determines thought, a concept known as linguistic determinism. They suggested that the vocabulary and structure of a language influence how its speakers think and perceive reality.
564
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
620
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
960
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
698